Our Mission: Immunotherapy for All – Improving Cancer Patient Response Rates in the Immunocompetent and Immunocompromised
Immunotherapy has changed the treatment paradigm in oncology. Unfortunately, many patients do not respond to immunotherapy and patients can experience severe side-effects.
Activate’s proprietary “nanolipogel” (NLG) nanotechnology can encapsulate pairs of multiple drug classes to create novel (and patentable) drug pairings including nucleic acid, protein and small molecules. We have developed proprietary methods to control the release of these different drugs so that they reach their targets. We can deliver our medicine to the right place, at the right time, for the right length of time. This increases the efficacy and reduces systemic exposure and toxicities of immune therapeutics.
Robust and Durable Anti-tumor Responses
Activate’s novel formulations of drug combinations stimulate both the innate and adaptive arms of the immune system to support robust and durable anti-tumor responses.